Additionally, immunomodulatory drugs (IMiDS), a common therapy in MM patients, enhance dendritic cell (DC) antigen presentation, resulting in the activation of CD4+ and CD8+ T lymphocytes and increased IFN-γ production [25]. The gene discussed is CD8A; the disease is Miyoshi myopathy.